EANS-News: AGENNIX AG / Agennix AG Announces Data from Talactoferrin Phase II Trial in Severe Sepsis to be Presented at 40th Critical Care Congress of the Society of Critical Care Medicine

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and Houston,
TX, January 12, 2011 - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced that new and more detailed data from a Phase II trial in severe sepsis
with talactoferrin, an oral biologic therapy with immunomodulatory and
antibacterial properties, will be presented at the 40th Critical Care Congress
of the Society of Critical Care Medicine, to be held January 15-19, 2011 in San
Diego, California.

Talactoferrin-related presentations are as follows:

"Talactoferrin alfa reduces 3 and 6 month all-cause mortality in patients with
severe sepsis," will be part of the oral session, "Infectious Disease-Sepsis,"
to be held on January 16, 2011, 3:00-5:00 PM.

"Talactoferrin may confer increased survival in patients with septic shock and
systolic cardiac dysfunction," will be presented as a poster presentation in the
Therapeutics-Drugs and Pharmacokinetics-2 category.

About talactoferrin
Talactoferrin is an oral biologic therapy with immunomodulatory and
antibacterial properties, which is being studied for the treatment of cancer and
severe sepsis. Talactoferrin has demonstrated activity in randomized,
double-blind, placebo-controlled Phase II studies in non-small cell lung cancer
(NSCLC), as well as in severe sepsis. As a result of the promising results from
Phase II studies, two Phase III trials with talactoferrin in NSCLC have been
initiated. NSCLC is one of the most common types of cancer worldwide and the
most frequent cause of cancer death. Agennix also plans to develop
talactoferrin further for the treatment of severe sepsis and expects to initiate
the Phase II portion of a Phase II/III trial in that indication in March/April
2011. Talactoferrin has been shown to be very well tolerated in these patient
populations.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company´s most advanced program is talactoferrin, an
oral therapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as well as in
severe sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program further
for the treatment of severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; and a topical
gel form of talactoferrin for diabetic foot ulcers. Agennix´s registered seat is
in Heidelberg, Germany. The Company has three sites of operation:
Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. There can be no guarantee that the Company will move talactoferrin
forward in development for severe sepsis in a timely manner, if at all, or that
talactoferrin will ultimately be approved for sale in any indication in any
country. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.

Further inquiry note:
Agennix AG
Barbara Mueller
Manager, Investor Relations &
Corporate Communications
Phone: +49 (0)89 8565 2693
[email protected]

In the U.S.: Laurie Doyle
Senior Director, Investor Relations &
Corporate Communications
Phone: +1 609 524 5884
[email protected]

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0)89 210 228 0
[email protected]

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: [email protected]
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print